Skip to main content

Advertisement

Table 4 Adverse events

From: Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Patients with AEs and SAEs n (%)
SAEs* 1 (14)
AEs leading to study drug discontinuation 1**
AEs reported in ≥2 patients  
   Upper respiratory tract infection 5 (71)
   Rash 4 (57)
   Pharyngitis 3 (43)
   Nasopharyngitis 3 (43)
   Vomiting 3 (43)
   Diarrhea 2 (29)
   Rhinitis 2 (29)
   Sleep disorder 2 (29)
   Cough 2 (29)
   Pharyngolaryngeal pain 2 (29)
   Acne 2 (29)
  1. *One patient experienced vertigo, considered as a SAE, which resolved during treatment. ** pregnancy